Maat Pharma

3 trials 1 recruiting Commercial sponsor

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

7 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 1 Phase II: 2

Oversight events:

1 serious breach 1 unexpected event across 2 trials

View oversight register →

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Acute graft versus host disease in intestine 1 Allogenic stem cell transplantation 1

Top IMPs

ALLOGENEIC FAECAL MICROBIOTA, POOLED 3

All trials

3 total

A medical research to evaluate if MaaT013 is safe and helps children and adolescent with GI-aGvHD after failed two prior therapies. Pending

2025-524302-15-00 Phase II 4 countries ALLOGENEIC FAECAL MICROBIOTA, POOLED
A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop… Recruiting

2022-501831-18-00 Phase II 5 countries ALLOGENEIC FAECAL MICROBIOTA, POOLED
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib… Ended

2024-513023-17-00 Phase III 6 countries ALLOGENEIC FAECAL MICROBIOTA, POOLED

Showing 1–3 of 3 trials

← All sponsors A–Z